Bryant Vo
Optometrist · Irvine, CANPI 1790970812
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Sight Sciences, Inc. accounts for 96.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $10,691 and has fallen 93.8% since, to $663 in 2025. Among optometrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $239.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$33K
- Bausch & Lomb Americas Inc.$257
- Lumenis BE Inc$137
- Kala Pharmaceuticals, Inc.$136
- Glaukos Corporation$128
- Lumenis, Inc$123
- plus $439 from 6 others
What the payments were for
- Consulting fees$17,47551%
- Speaking & faculty fees$12,55037%
- Travel & lodging$7082%
- Food & beverage$3,43610%
- Entertainment$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 122 | $32,984 |
| Bausch & Lomb Americas Inc. | 3 | $257 |
| Lumenis BE Inc | 1 | $137 |
| Kala Pharmaceuticals, Inc. | 2 | $136 |
| Glaukos Corporation | 1 | $128 |
| Lumenis, Inc | 1 | $123 |
| Heru, Inc. | 1 | $115 |
| Coopervision Inc. | 4 | $107 |
| Visioneering Technologies, Inc. | 1 | $92 |
| Optos, Inc. | 4 | $65 |
| Alcon | 2 | $43 |
| Boehringer Ingelheim | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TearCare SmartLid$14,762
- TEARCARE(TM) (2.2) SYSTEM KIT$14,762
- TEARCARE SYSTEM$12,550
- TearCare$3,500
- OMNI(R) SURGICAL SYSTEM (US)$641
- INFUSE$142
- optilight$137
- KXL System$128
- Photrexa$128
- Lumenis Pulse 120H$123
- EYSUVIS$120
- Heru HMD$115
How this compares
$34,204 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 20 | $568 |
| Prednisolone Acetate | 12 | $253 |
| Cephalexin | 13 | $81 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Irvine
- Steve YoelinNewport Beach$4.1M
- Matthew GellerSpring Valley$3.5M
- Melissa EricksonDavis$522K
- Omid KhodaiLake Forest$499K
- Jason TuSan Diego$351K
- Scott SchachterPismo Beach$312K
- Alicia LauSan Diego$300K
- Vin DangBakersfield$284K
- Steven FerrucciSepulveda$272K
- Katie ChuRosemead$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.